Batoclimab
Thyroid Eye Disease (TED)
Key Facts
About Immunovant
Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.
View full company profileAbout Immunovant
Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.
View full company profileAbout Immunovant
Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.
View full company profileAbout Immunovant
Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.
View full company profileTherapeutic Areas
Other Thyroid Eye Disease (TED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oral K9 | Inflammasome Therapeutics | Phase I |
| LASN01 | Lassen Therapeutics | Phase 1 |
| IMVT-1402 | Immunovant | Phase 2 |
| VRDN-001 | Viridian Therapeutics | Phase 3 |
| VRDN-003 | Viridian Therapeutics | Phase 1/2 |